(1,1-difluoro-pentadecyl)-phosphonic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: (1,1-difluoro-pentadecyl)-phosphonic acid
• 英文别名: (1,1-difluoro-pentadecyl)phosphonic acid；(1,1-difluoropentadecyl)phosphonic acid；1,1-difluoropentadecylphosphonic acid
• 化学式: C₁₅H₃₁F₂O₃P
• 分子量: 328.38
• InChiKey: YGXPAGSHLFJKFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  21
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  溴代十四烷 在 三甲基溴硅烷 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.5h， 生成 (1,1-difluoro-pentadecyl)-phosphonic acid
  参考文献：
  名称：

  [EN] LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE
  [FR] AGONISTES ET ANTAGONISTES DU RECEPTEUR LPA ET METHODES D'UTILISATION

  摘要：

  公开号：

  WO2005032494A3

文献信息

• [EN] LPA RECEPTOR AGONISTS AND ANTAGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS DE LPA ET ANTAGONISTES
  申请人：RXBIO INC

  公开号：WO2010051053A1

  公开（公告）日：2010-05-06

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including treating cancer, producing radioprotection and/or radiomitigation, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermato logical condition.

  揭示了按照式(I)的化合物，以及包括这些化合物的药物组合物。还揭示了使用这些化合物的方法，这些方法具有作为LPA受体激动剂或拮抗剂的活性；这些方法包括治疗癌症、产生放射保护和/或减轻放射损伤、增强细胞增殖、治疗伤口、治疗凋亡或在细胞、组织或器官中保护或恢复功能、培养细胞、保护器官或组织功能，以及治疗皮肤病理条件。
• Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
  申请人：Miller D. Duane

  公开号：US20060270634A1

  公开（公告）日：2006-11-30

  Disclosed are compositions that modulate the effects of extracellular LPA receptors, the intracellular PPARγ receptor, and autotaxin, and methods for their use.

  揭示了调节细胞外LPA受体、细胞内PPARγ受体和自体脂肪酶效应的组合物，以及它们的使用方法。
• LPA receptor agonists and antagonists and methods of use
  申请人：Miller D. Duane

  公开号：US20060009507A1

  公开（公告）日：2006-01-12

  The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及公式（I）所示的化合物，以及包括这些化合物的制药组合物。还公开了使用这些化合物的方法，这些化合物具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括抑制LPA受体上的LPA活性，调节LPA受体活性，治疗癌症，增强细胞增殖，治疗伤口，治疗凋亡或在细胞、组织或器官中保持或恢复功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• LPA Receptor Agonists and Antagonists and Methods of Use
  申请人：Miller D. Duane

  公开号：US20080090783A1

  公开（公告）日：2008-04-17

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.

  本发明涉及化合物(I)及包含该化合物的药物组合物。还揭示了使用这些化合物的方法，这些方法具有作为LPA受体激动剂或拮抗剂的活性；这些方法包括抑制LPA受体上的LPA活性，调节LPA受体活性，治疗癌症，增强细胞增殖，治疗创伤，治疗凋亡或保护或恢复细胞、组织或器官的功能，培养细胞，保护器官或组织功能，以及治疗皮肤病症。
• LPA Receptor Agonists and Antagonists
  申请人：Gududuru Veeresh

  公开号：US20120010424A1

  公开（公告）日：2012-01-12

  Disclosed are compounds according to formula (I) as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including treating cancer, producing radioprotection and/or radiomitigation, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermato logical condition.

  本发明涉及公式（I）所示的化合物，以及包括这些化合物的制药组合物。本发明还涉及使用这些化合物的方法，这些化合物具有作为LPA受体的激动剂或拮抗剂的活性；这些方法包括治疗癌症、产生放射保护和/或减轻放射损伤、增强细胞增殖、治疗伤口、治疗凋亡或保护或恢复细胞、组织或器官的功能、培养细胞、保护器官或组织功能，以及治疗皮肤病症。